Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q9BYC9
UPID:
RM20_HUMAN
Alternative names:
39S ribosomal protein L20, mitochondrial
Alternative UPACC:
Q9BYC9; B2RE41; B7Z746
Background:
The Large ribosomal subunit protein bL20m, also known as 39S ribosomal protein L20, mitochondrial, plays a crucial role in the synthesis of proteins within the mitochondria. Its involvement in the mitochondrial ribosome highlights its importance in cellular energy production and overall mitochondrial function.
Therapeutic significance:
Understanding the role of Large ribosomal subunit protein bL20m could open doors to potential therapeutic strategies. Its pivotal function in protein synthesis within mitochondria suggests that targeting this protein could influence mitochondrial diseases and disorders related to cellular energy metabolism.